Fig. 4

IL20RB activates STAT3 phosphorylation to promote pancreatic cancer stemness and chemotherapy resistance. A Western blot analysis of IL20RB, STAT3 and p-STAT3 (Tyr705) proteins in pancreatic cancer cell line MIA PaCa-2. B Western blot analysis of IL20RB, STAT3 and p-STAT3 (Tyr705) in pancreatic cancer cell line PANC-1. C Real-time quantitative PCR analysis of the mRNA expression of IL20RB, NANOG, SOX2 and POU5F1 in MIA PaCa-2 treated with the vehicle or STAT3 inhibitor (Stattic), respectively (n = 3 in each group). (D) Western blot analysis of IL20RB, STAT3, p-STAT3 (Tyr705), NANOG and SOX2 proteins in MIA PaCa-2 after the vehicle or Stattic treatment. E Sphere-forming assay and statistical analysis of MIA PaCa-2 after treatment with the vehicle or Stattic (n = 3 per group). F Colony formation assay and statistical analysis of MIA PaCa-2 treated with 10 nM gemcitabine for 24 h with or without Stattic (n = 3 per group). G Representative immunofluorescence images of IL20RB, pan-CK and p-STAT3 in human pancreatic cancer tissue sections, scale bar = 40 µm